Close Menu

NEW YORK (GenomeWeb News) – Reagents maker Link Technologies said today that it will sell RiboTask's nucleic acid monomers, under a new license agreement.

Link, a Scottish company, will make and commercialize RiboTask's unlocked-nucleic acid (UNA) monomer phosphoramadite reagents, which are used to enable fine-tuning of oligonucleotide stability in siRNA gene silencing and other applications.

Patents for the therapeutic use of UNA oligonucleotides are held by MDRNA, according to Link.

Financial terms of the agreement were not released.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.

Oct
28
Sponsored by
NRGene

Molecular breeding methods such as genomic selection and genome-wide association studies often require high-density genotypic data from many samples, but the cost and complexity of genotyping at this scale may be prohibitive.

Nov
11
Sponsored by
Illumina

Selective breeding represents an efficient approach to increase production of aquaculture species by means of improving traits, such as rapid growth, product quality, and disease resistance.